First European Patient Dosed in Phase I Trial Of Novel CD30-Directed ADC FOR Lymphomas – The START Center for Cancer Research

The START Center for Cancer Research shared a post on LinkedIn:

“We are thrilled to announce that we have dosed the first European patient in the Phase 1, open-label, multicenter study exploring a novel CD30-directed antibody-drug conjugate in patients with various relapsed/refractory lymphomas, including T-cell lymphoma, classical Hodgkin lymphoma and diffuse large B-cell lymphoma at START Madrid-FJD.

This enrollment and dosing milestone is a significant step forward in our mission to advance innovative treatments in oncology, where we hope to address an unmet medical need for this patient population.

We are proud to lead this effort and look forward to the hope this investigational therapy will bring to patients across Europe.”

Source: The START Center for Cancer Research/LinkedIn